Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1072-1079

  Papathanou, Maria ^a,b,c   van der Laan, Rika ^a,d   Jenner, Peter ^b   Rose, Sarah ^b   Mccreary, Andrew C ^a,e  

^a Chemical Design and Synthesis Unit   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Karolinska Institutet   (Sweden)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

6 OHDA lesioned rats; AIMs; Dyskinesia; Intraduodenal levodopa infusion; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DYSKINESIA; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

6-OHDA-LESIONED RATS; AIMS; DYSKINESIA; INTRADUODENAL LEVODOPA INFUSION; PARKINSON'S DISEASE;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DYSKINESIAS; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84881515809     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25218     Document Type: Article

References (55)

1. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
2. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006;2:382-392.
3. Stocchi F. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment. Neurodegener Dis 2010;7:213-215.
4. Nyholm D, Nilsson Remahl AIM, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
5. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
6. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23( 10 Suppl):S109-S115.
7. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009;119:345-348.
8. Schuh LA, Bennett JP, Jr. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
9. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001;22:93-94.
10. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
11. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27.
12. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
13. Marin C, Aguilar E, Obeso JA. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov Disord 2006;21:646-653.
14. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306-314.
15. Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 2005;192:184-193.
16. Hauser RA. IPX066: a novel carbidopa-levodopa extended-release formulation. Expert Rev Neurother 2012;12:133-140.
17. Jenner P, McCreary AC, Scheller DK. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011;118:1691-1702.
18. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001;104:343-348.
19. Nyholm D, Lewander T, Johansson A, LeWitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
20. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-1085.
21. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1986.
22. Papathanou M, Rose S, McCreary A, Jenner P. Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. Eur J Neurosci 2011;33:2247-2254.
23. Remie R, Rensema JW, Havinga R, Kuipers F. The permanent bile fistula rat model. Progr Pharmacol Clin Pharmacol 1991;8:127-145.
24. Thrivikraman KV, Huot RL, Plotsky PM. Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res Protoc 2002;10:84-94.
25. van Dongen JJ, Remie R, Rensema JW, van Wunnik GHJ. Permanent cannulation of the jugular vein. Manual of microsurgery on the laboratory rat. 1st ed. Amsterdam: Elsevier Science Publishers; 1990:157-170.
26. Rose S, Jenner P, Marsden CD. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat. J Pharm Pharmacol 1993;45:725-730.
27. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-dopa delivery using rAAV vectors. Brain 2005;128:559-569.
28. Cenci, Lee, Bjorklund. L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706.
29. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002;15:120-132.
30. de la Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
31. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-897.
32. Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa. Eur Neuropsychopharmacol 2010;20:683-687.
33. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
34. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
35. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-89.
36. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
37. Cenci MA, Lindgren HS. Advances in understanding L-Dopa-induced dyskinesia. Curr Opin Neurobiol 2007;17:665-671.
38. Mura A, Mintz M, Feldon J. Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-Dopa) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 2002;177:252-264.
39. Truong L, Allbutt H, Kassiou M, Henderson JM. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 2006;169:1-9.
40. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
41. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
42. Parkinson Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-570.
43. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53:1012-1019.
44. Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother 2004;4:589-599.
45. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 2002;58:1S-8S.
46. Jenner P. Molecular mechanisms of L-Dopa-induced dyskinesia. Nat Rev Neurosci 2008;9:665-677.
47. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149.
48. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson Disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2007;31:151-166.
49. Nutt JG, Carter JH, Woodward W, Hammerstad JP, Gancher ST. Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions. Mov Disord 1993;8:139-143.
50. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-1267.
51. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009;10:677-691.
52. Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat Disord 2009;15(Suppl 4):S93-S96.
53. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008;24:2883-2895.
54. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-276.
55. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010;25:858-866.